{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:33Z","timestamp":1793895993331,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020797","name":"NanoMedicines Innovation Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115038","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:23:25Z","timestamp":1779319405000},"page":"115038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanomedicines from the patient perspective \u2013 30\u00a0years after PEGylated liposomal doxorubicin"],"prefix":"10.1016","volume":"396","author":[{"given":"Lucy","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sehdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115038_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115038_bb0010","author":"Global Newswire"},{"key":"10.1016\/j.jconrel.2026.115038_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113731","article-title":"Cancer nanomedicine from a clinician-scientist perspective: lessons and prospects","volume":"382","author":"Gabizon","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115038_bb0020","first-page":"1","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0025","doi-asserted-by":"crossref","first-page":"13983","DOI":"10.1021\/acsnano.4c00182","article-title":"Mechanisms and barriers in nanomedicine: progress in the field and future directions","volume":"18","author":"Anchordoquy","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115038_bb0030","series-title":"Classic Kaposi Sarcoma: Clinical Features, Staging, Diagnosis, and Treatment","first-page":"1","author":"Krown","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115038_bb0035","series-title":"AIDS-related Kaposi Sarcoma: Staging and Treatment","first-page":"1","author":"Goopman","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115038_bb0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djq134","article-title":"Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion","volume":"102","author":"Lodi","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2026.115038_bb0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/00002030-199812000-00009","article-title":"Kaposi\u2019s sarcoma in HIV infection: impact on opportunistic infections and survival","volume":"12","author":"Brodt","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2026.115038_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.critrevonc.2004.10.009","article-title":"Treatments of AIDS-related Kaposi\u2019s sarcoma","volume":"53","author":"Aversa","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0009-9236(97)90162-4","article-title":"Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"61","author":"Amantea","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115038_bb0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115038_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/898146","article-title":"Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer","volume":"2013","author":"Pisano","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115038_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminoncol.2004.08.004","article-title":"Liposomal anthracycline treatment for ovarian cancer","volume":"31","author":"Markman","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","article-title":"Role of pegylated liposomal doxorubicin in ovarian cancer","volume":"96","author":"Thigpen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.gore.2015.06.009","article-title":"The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: a low-value intervention?","volume":"13","author":"Cohn","year":"2015","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.jconrel.2026.115038_bb0090","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/annonc\/mdf275","article-title":"A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK","volume":"13","author":"Smith","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0095","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/sj.bjc.6601228","article-title":"Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain","volume":"89","author":"Ojeda","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115038_bb0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/j.seminoncol.2004.08.008","article-title":"Pharmacoeconomics of liposomal anthracycline therapy","volume":"31","author":"Bennett","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115038_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115038_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115038_bb0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115038_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0130","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cancers17172827","article-title":"Liposomal doxorubicin, but not platinum-taxane, supports MHC-II expression and immune maturation in the ovarian tumor microenvironment","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115038_bb0135","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115038_bb0140","article-title":"Time toxicity of systemic anticancer therapy for metastatic lung cancer in routine clinical practice: a nationwide cohort study","author":"Ording","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.jconrel.2026.115038_bb0145","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial","volume":"19","author":"Gupta","year":"2023","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.jconrel.2026.115038_bb0150","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40258-022-00753-w","article-title":"Productivity loss and indirect costs for patients newly diagnosed with early- versus late-stage cancer in the USA: a large-scale observational research study","volume":"20","author":"Cong","year":"2022","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.jconrel.2026.115038_bb0155","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/oncolo\/oyae187","article-title":"Patients\u2019 considerations of time toxicity when assessing cancer treatments with marginal benefit","author":"Gupta","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2026.115038_bb0160","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115038_bb0165","first-page":"1388","article-title":"Vincristine sulfate liposomes injection (VSLI, Marqibo): results from a phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias","author":"Shah","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2026.115038_bb0170","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/cncr.24359","article-title":"Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study","volume":"115","author":"Rodriguez","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.115038_bb0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12446","article-title":"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo\u00ae) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive","volume":"162","author":"Hagemeister","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0180","series-title":"Withdrawal of Approval of New Drug Application for MARQIBO (VinCRIStine Sulfate LIPOSOME Injection), 5\u00a0milligrams\/5\u00a0milliliters","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115038_bb0185","series-title":"FDA Withdraws Approval of MARQIBO","author":"ASH Clinical News","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115038_bb0190","first-page":"1","article-title":"Vincristine Sulfate Liposome Injection with combination chemotherapy for children, adolescents, and young adults with relapsed acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia and lymphoma consortium trial","author":"Shah","year":"2025","journal-title":"Pediatr. Blood &Cancer"},{"key":"10.1016\/j.jconrel.2026.115038_bb0195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0205","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/bloodadvances.2024014279","article-title":"Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS","volume":"9","author":"Cluzeau","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2026.115038_bb0210","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0215","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","article-title":"CREST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","author":"Mehta","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2026.115038_bb0220","series-title":"Daunorubicin and Cytarabine Liposome (Vyxeos)","author":"Canadian Agency for Drugs and Technologies in Health","year":"2021"},{"key":"10.1016\/j.jconrel.2026.115038_bb0225","series-title":"Acute Myeloid Leukemia: Induction Therapy in Medically Fit Adults","first-page":"1","author":"Larson","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115038_bb0230","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2217\/nnm.14.150","article-title":"Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy","volume":"9","author":"Bosetti","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115038_bb0235","article-title":"Reporting time toxicity in prospective cancer clinical trials: a scoping review","volume":"32","author":"Quinn","year":"2025","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jconrel.2026.115038_bb0240","first-page":"129","article-title":"Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions","volume":"37","author":"Faulkner","year":"2023","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.jconrel.2026.115038_bb0245","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41591-023-02445-x","article-title":"Considerations for patient and public involvement and engagement in health research","volume":"29","author":"Aiyegbusi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115038_bb0250","article-title":"Patient and public involvement in the design of an international clinical trial: real world experience","volume":"10","author":"Simons","year":"2024","journal-title":"Res. Involv. Engag."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:51:06Z","timestamp":1793893866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S0168365926004414"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115038","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicines from the patient perspective \u2013 30\u00a0years after PEGylated liposomal doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115038"}}